Discovery and refinement of a new structural class of potent peptide deformylase inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 1, 2007, Pages 10-20

  Boularot, Adrien ^a   Giglione, Carmela ^a   Petit, Sylvain ^a   Duroc, Yann ^a   De Sousa, Rodolphe Alves ^a   Larue, Valéry ^a   Cresteil, Thierry ^a   Dardel, Frédéric ^a   Artaud, Isabelle ^a   Meinnel, Thierry ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 BROMO 1H INDOL 3 YL) N HYDROXYACETAMIDE; ACETAMIDE DERIVATIVE; ACTINONIN; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; CELL STRAIN KB; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; IC 50; MINIMUM INHIBITORY CONCENTRATION; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; APOPTOSIS; BACILLUS STEAROTHERMOPHILUS; BACILLUS SUBTILIS; ESCHERICHIA COLI; HUMANS; HYDROXAMIC ACIDS; INDOLES; KB CELLS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846197066     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060910c     Document Type: Article

References (41)

1. Hughes, D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Genet. 2003, 4, 432-441.
2. Miesel, L.; Greene, J.; Black, T. A. Genetic strategies for antibacterial drug discovery. Nat. Rev. Genet. 2003, 4, 442-456.
3. Mills, S. D. When will the genomics investment pay off for antibacterial discovery? Biochem. Pharmacol. 2006, 71, 1096-1102.
4. Boularot, A.; Giglione, C.; Artaud, I.; Meinnel, T. Structure-activity relationship and therapeutic potential of peptide deformylase inhibitors. Curr. Opin. Invest. Drugs 2004, 5, 809-822.
5. Jain, R.; Chen, D.; White, R. J.; Patel, D. V.; Yuan, Z. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 2005, 12, 1607-1621.
6. Lee, M. D.; Antczak, C.; Li, Y.; Sirotnak, F. M.; Bornmann, W. G.; Scheinberg, D. A. A new human peptide deformylase inhibitable by actinonin. Biochem. Biophvs. Res. Commun. 2003, 312, 309-315.
7. Nguyen, K. T.; Hu, X.; Colton, C.; Chakrabarti, R.; Zhu, M. X.; Pei, D. Characterization of a human peptide deformylase: Implications for antibacterial drug design. Biochemistry 2003, 42, 9952-9958.
8. Serero, A.; Giglione, C.; Sardini, A.; Martinez Sanz, J.; Meinnel, T. An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J. Biol. Chem. 2003, 278, 52953-52963.
9. Giglione, C.; Pierre, M.; Meinnel, T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol. 2000, 36, 1197-1205.
10. Yuan, Z. Trias, J.; White, R. J. Deformylase as a novel antibacterial target. Drug Discovery Today 2001, 6, 954-961.
11. Giglione, C.; Boularot, A.; Meinnel, T. Protein N-terminal methionine excision. Cell. Mol. Life Sci. 2004, 61, 1455-1474.
12. Lee, M. D.; She, Y.; Soskis, M. J.; Borella, C. P.; Gardner, J. R.; Hayes, P. A.; Dy, B. M.; Heaney, M. L.; Philips, M. R.; Bornmann, W. G.; Sirotnak, F. M.; Scheinberg, D. A. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J. Clin. Invest. 2004, 114, 1107-1116.
13. Leszczyniecka, M.; Bhatia, U.; Cueto, M.; Nirmala, N. R.; Towbin, H.; Vattay, A.; Wang, B.; Zabludoff, S.; Phillips, P. E. MAPID, a novel methionine aminopeptidase family member is overexpressed in colon cancer. Oncogene, in press.
14. Xu, Y.; Lai, L. T.; Gabrilove, J. L.; Scheinberg, D. A. Antitumor activity of actinonin in vitro and in vivo. Clin. Cancer Res. 1998, 4, 171-176.
15. Grujic, M.; Renko, M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett. 2002, 182, 113-119.
16. Guilloteau, J. P.; Mathieu, M.; Giglione, C.; Blanc, V.; Dupuy, A.; Chevrier, M.; Gil, P.; Famechon, A.; Meinnel, T.; Mikol, V. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. Mol. Biol. 2002, 320, 951-962.
17. Ragusa, S.; Mouchet, P.; Lazennec, C.; Dive, V.; Meinnel, T. Substrate recognition and selectivity of peptide deformylase. Similarities and differences with metzincins and thermolysin. J. Mol. Biol. 1999, 289, 1445-1457.
18. Fieulaine, S.; Juillan-Binard, C.; Serero, A.; Dardel, F.; Giglione, C.; Meinnel, T.; Ferrer, J. L. The crystal structure of mitochondrial (type 1A) peptide deformylase provides clear guidelines for the design of inhibitors specific for the bacterial forms. J. Biol. Chem. 2005, 280, 42315-42324.
19. Serero, A.; Giglione, C.; Meinnel, T. Distinctive features of the two classes of eukaryotic peptide deformylases. J. Mol. Biol 2001, 314, 695-708.
20. Meinnel, T.; Blanquet, S.; Dardel, F. A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase. J. Mol. Biol. 1996, 262, 375-386.
21. Meinnel, T.; Patiny, L.; Ragusa, S.; Blanquet, S. Design and synthesis of substrate analogue inhibitors of peptide deformylase. Biochemistry 1999, 38, 4287-4295.
22. Mayer, M.; Meyer, B. Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 2001, 123, 6108-6117.
23. Van Aller, G. S.; Nandigama, R.; Petit, C. M.; Dewolf, W. E., Jr.; Quinn, C. J.; Aubart, K. M.; Zalacain, M.; Christensen, S. B.; Copeland, R. A.; Lai, Z. Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin. Biochemistry 2005, 44, 253-260.
24. Nguyen, K. T.; Hu, X.; Pei, D. Slow-binding inhibition of peptide deformylase by cyclic peptidomimetics as revealed by a new spectrophotometric assay. Bioorg. Chem. 2004, 32, 178-191.
25. Morrison, J. F.; Walsh, C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 1988, 61, 201-301.
26. Henderson, P. J. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem. J. 1972, 127, 321-333.
27. Haas, M.; Beyer, D.; Gahlmann, R.; Freiberg, C. YkrB is the main peptide deformylase in Bacillus subtilis, a eubacterium containing two functional peptide deformylases. Microbiology 2001, 147, 1783-1791.
28. Giglione, C.; Meinnel, T. Resistance to anti-peptide deformylase drugs. Expert Opin. Ther. Targets 2001, 5, 415-418.
29. Nilsson, A. I.; Zorzet, A.; Kanth, A.; Dahlstrom, S.; Berg, O. G.; Andersson, D. I. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6976-6981.
30. Clements, J. M.; Beckett, R. P.; Brown, A.; Catlin, G.; Lobell, M.; Palan, S.; Thomas, W.; Whittaker, M.; Wood, S.; Salama, S.; Baker, P. J.; Rodgers, H. F.; Barynin, V.; Rice, D. W.; Hunter, M. G. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 2001, 45, 563-570.
31. Apfel, C.; Banner, D. W.; Bur, D.; Dietz, M.; Hirata, T.; Hubschwerlen, C.; Locher, H.; Page, M. G.; Pirson, W.; Rosse, G.; Specklin, J. L. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J. Med. Chem. 2000, 43, 2324-2331.
32. Ragusa, S.; Blanquet, S.; Meinnel, T. Control of peptide deformylase activity by metal cations. J. Mol. Biol. 1998, 280, 515-523.
33. Lazennec, C.; Meinnel, T. Formate dehydrogenase-coupled spectrophotometric assay of peptide deformylase. Anal. Biochem. 1997, 244, 180-182.
34. Dardel, F.; Ragusa, S.; Lazennec, C.; Blanquet, S.; Meinnel, T. Solution structure of nickel-peptide deformylase. J. Mol. Biol. 1998, 280, 501-513.
35. Tisne, C.; Dardel, F. Optimisation of a peptide library for screening specific RNA ligands by flow-injection NMR. Comb. Chem. High Throughput Screening 2002, 5, 523-529.
36. Xiang, J.; Christensen, S.; Liao, X. Peptide deformylase inhibitors, Patent WO-02070653. 2002.
37. Anagnostopoulos, C.; Crawford, I. P. Transformation studies on the linkage of markers in the tryptophan pathway in Bacillus subtilis. Proc. Natl Acad. Sci. U.S.A. 1961, 47, 378-390.
38. Miller, H. I.; Friedman, D. I. An E. coli gene product required for λ site-specific recombination. Cell 1980, 20, 711-719.
39. Hirel, P.-H.; Lévêque, F.; Mellot, P.; Dardel, F.; Panvert, M.; Mechulam, Y.; Fayat, G. Genetic engineering of methionyl-tRNA synthetase: in vitro regeneration of an active synthetase by proteolytic cleavage of a methionyl-tRNA synthetase-β-galactosidase chimeric protein. Biochimie 1988, 70, 773-782.
40. Singer, M.; Baker, T. A.; Schnitzler, G.; Deischel, S. M.; Goel, M.; Dove, W.; Jaacks, K. J.; Grossman, A. D.; Erickson, J. W.; Gross, C. A. A collection of strains containing genetically linked alternating antibiotic resistance elements for genetic mapping of Escherichia coli. Microbiol. Rev. 1989, 53, 1-24.
41. Molteni, V.; He, X.; Nabakka, J.; Yang, K.; Kreusch, A.; Gordon, P.; Bursulaya, B.; Warner, I.; Shin, T.; Biorac, T.; Ryder, N. S.; Goldberg, R.; Doughty, J.; He, Y. Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 1477-1481.